Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity.

Zoghlami A, Roussel F, Sabourin JC, Kuhn JM, Marie JP, Dehesdin D, Choussy O.

Eur Ann Otorhinolaryngol Head Neck Dis. 2014 Feb;131(1):7-13. doi: 10.1016/j.anorl.2013.01.004. Epub 2013 Jul 9.

2.

The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.

Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK.

Clin Endocrinol (Oxf). 2006 Sep;65(3):364-8.

PMID:
16918957
3.

Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.

Lukas J, Drabek J, Dudesek B, Vazan P, Stranska J, Jancik S, Mackova M, Syrucek M, Lukas D, Duskova J, Dundr P, Hintnausova B, Jiskra J.

Exp Clin Endocrinol Diabetes. 2014 May;122(5):268-72. doi: 10.1055/s-0034-1372624. Epub 2014 May 16.

PMID:
24839220
4.

BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.

Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M.

Medicine (Baltimore). 2012 Sep;91(5):274-86. doi: 10.1097/MD.0b013e31826a9c71. Review.

5.

The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.

Daliri M, Abbaszadegan MR, Bahar MM, Arabi A, Yadollahi M, Ghafari A, Taghehchian N, Zakavi SR.

Endocr Res. 2014;39(4):189-93. doi: 10.3109/07435800.2013.879169. Epub 2014 Mar 28.

PMID:
24679337
6.

The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.

Pelizzo MR, Dobrinja C, Casal Ide E, Zane M, Lora O, Toniato A, Mian C, Barollo S, Izuzquiza M, Guerrini J, De Manzini N, Merante Boschin I, Rubello D.

Biomed Pharmacother. 2014 May;68(4):413-7. doi: 10.1016/j.biopha.2014.03.008. Epub 2014 Mar 18.

PMID:
24721322
7.
8.

Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.

Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, Coyne C, Stang MT, McCoy KL, Nikiforova MN, Nikiforov YE, Yip L.

Ann Surg Oncol. 2011 Dec;18(13):3566-71. doi: 10.1245/s10434-011-1781-5. Epub 2011 May 19.

PMID:
21594703
9.

The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.

Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, Piaggi P, Pinchera A, Vitti P, Basolo F.

J Clin Endocrinol Metab. 2012 Dec;97(12):4390-8. doi: 10.1210/jc.2012-1775. Epub 2012 Oct 12.

PMID:
23066120
10.

The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?

Walczyk A, Kowalska A, Kowalik A, Sygut J, Wypiórkiewicz E, Chodurska R, Pięciak L, Góźdź S.

Clin Endocrinol (Oxf). 2014 Jun;80(6):899-904. doi: 10.1111/cen.12386. Epub 2014 Jan 16.

PMID:
24354346
11.

The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.

Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK.

Clin Endocrinol (Oxf). 2005 Nov;63(5):588-93.

PMID:
16268813
12.

The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.

Barbaro D, Incensati RM, Materazzi G, Boni G, Grosso M, Panicucci E, Lapi P, Pasquini C, Miccoli P.

Endocrine. 2014 Apr;45(3):462-8. doi: 10.1007/s12020-013-0029-5. Epub 2013 Aug 8.

PMID:
23925579
13.

[An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].

Gong RX, Zhou Y, Luo SH, Zhang L, Zhou B.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2009 Jun;26(3):310-3. doi: 10.3760/cma.j.issn.1003-9406.2009.03.016. Chinese.

PMID:
19504446
14.

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.

Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F.

J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9. doi: 10.1210/jc.2008-0607. Epub 2008 Aug 5.

PMID:
18682506
15.

BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.

Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.

Clin Endocrinol (Oxf). 2008 Apr;68(4):618-34. Epub 2007 Dec 5.

PMID:
18070147
16.

BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.

Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A.

Endocr J. 2009;56(1):89-97. Epub 2008 Oct 8.

17.

The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry.

McKelvie PA, Chan F, Yu Y, Waring P, Gresshoff I, Farrell S, Williams RA.

Pathology. 2013 Dec;45(7):637-44. doi: 10.1097/PAT.0000000000000008.

PMID:
24247620
18.

BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.

Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo do H, Youn YK.

World J Surg. 2012 Feb;36(2):310-7. doi: 10.1007/s00268-011-1383-1.

PMID:
22190222
19.

Clinical significance of BRAF mutation in thyroid papillary cancer.

Fernandez IJ, Piccin O, Sciascia S, Cavicchi O, Repaci A, Vicennati V, Fiorentino M.

Otolaryngol Head Neck Surg. 2013 Jun;148(6):919-25. doi: 10.1177/0194599813481942. Epub 2013 Mar 12.

PMID:
23482475
20.

BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis.

Colanta A, Lin O, Tafe L, Ghossein R, Nafa K, Mitchell T, Ladanyi M, Arcila M.

Acta Cytol. 2011;55(6):563-9. doi: 10.1159/000333272. Epub 2011 Dec 9.

PMID:
22156467
Items per page

Supplemental Content

Write to the Help Desk